Pharmafile Logo
Pharmafocus logo
Advanced Search

rigosertib

Showing 1 posts of 1 posts found.

7-0_careers_taleobanner_900x600

Onconova says Baxalta ends $565 million drug development deal for rigosertib

March 8, 2016
Manufacturing and Production, Research and Development Baxalta, Onconova Therapeutics, drug development, rigosertib

Onconova Therapeutics says Baxalta has terminated its $565 million agreement to jointly develop the company’s lead drug candidate rigosertib. Baxalta …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025